A novel, synthetic antiinfective drug candidate, r-327, for the acute treatment of burn wounds and downstream sequelae
Active Project Grant Awarded Last action
- Award ID
- HT94252410840
- Recipient
-
Recce Pharmaceuticals LTD UEI NPJ4XBV6EHD7
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $2,000,000
Award facts
- Assistance listing
- 12.420 Military Medical Research and Development
- Completion date 74% complete
- Place of performance
- Australia
Award details come from USAspending.gov.
About this award
The U.S. Department of the Army Medical Command, through the Military Medical Research and Development (CFDA 12.420) program, awarded a $2,000,000 project grant to Recce Pharmaceuticals LTD, a foreign-owned for-profit organization based in Australia. The grant will fund the development of a novel, synthetic anti-infective drug candidate, R-327, for the acute treatment of burn wounds and downstream sequelae. The performance period for this grant is from August 1, 2024, to July 31, 2027.
Quick answers
Who received award HT94252410840?
HT94252410840 was awarded to Recce Pharmaceuticals LTD by Defense Health Agency (Department of Defense) on August 1, 2024.
How much is award HT94252410840 worth?
$2,000,000 has been obligated on HT94252410840.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award